Show simple item record

dc.contributor.authorConradie, F*
dc.contributor.authorMeintjes, G*
dc.contributor.authorHughes, J*
dc.contributor.authorMaartens, G*
dc.contributor.authorFerreira, H*
dc.contributor.authorSiwendu, S*
dc.contributor.authorMaster, I*
dc.contributor.authorNdjeka, N*
dc.date.accessioned2014-03-26T15:52:15Z
dc.date.available2014-03-26T15:52:15Z
dc.date.issued2014-03-26
dc.identifier.citationClinical access to Bedaquiline programme for the treatment of drug-resistant tuberculosis 2014, 104 (3):164 South African Medical Journalen_GB
dc.identifier.issn2078-5135
dc.identifier.issn0256-9574
dc.identifier.doi10.7196/samj.7263
dc.identifier.urihttp://hdl.handle.net/10144/314741
dc.description.abstractWhile clinical disease caused by drug-sensitive Mycobacterium tuberculosis (MTB) can usually be treated successfully, clinical disease caused by drug-insensitive MTB is associated with a poorer prognosis. In December 2012, a new drug, bedaquiline, was approved by the US Food and Drug Administration. This article documents the process whereby the National Department of Health, Right to Care and Médecins Sans Frontières obtained access to this medication for South Africans who might benefit from subsequent implementation of the Clinical Access to Bedaquiline Programme
dc.language.isoenen
dc.publisherHealth & Medical Publishing Groupen_GB
dc.relation.urlhttp://samj.org.za/index.php/samj/article/view/7263en_GB
dc.rightsPublished by: Health and Medical Publishing Group Archived on this site with kind permission of the Health and Medical Publishing Group and the South African Medical Association, [url]http://www.samj.org.za[/url]en_GB
dc.subjectAntibiotic Resistanceen_GB
dc.subjectHealth Policy/Access to Medecinesen_GB
dc.subjectTuberculosisen_GB
dc.titleClinical Access to Bedaquiline Programme for the treatment of drug-resistant tuberculosisen
dc.identifier.journalSouth African Medical Journalen_GB
refterms.dateFOA2019-03-04T11:11:29Z
html.description.abstractWhile clinical disease caused by drug-sensitive Mycobacterium tuberculosis (MTB) can usually be treated successfully, clinical disease caused by drug-insensitive MTB is associated with a poorer prognosis. In December 2012, a new drug, bedaquiline, was approved by the US Food and Drug Administration. This article documents the process whereby the National Department of Health, Right to Care and Médecins Sans Frontières obtained access to this medication for South Africans who might benefit from subsequent implementation of the Clinical Access to Bedaquiline Programme


Files in this item

Thumbnail
Name:
Conradie et al-2014-Clinical ...
Size:
89.40Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record